Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas

• Main Authors: Michalina Zajdel, Grzegorz Rymkiewicz, Maria Sromek, Maria Cieslikowska, Pawel Swoboda, Mariusz Kulinczak, Krzysztof Goryca, Zbigniew Bystydzienski, Katarzyna Blachnio, Beata Ostrowska, Anita Borysiuk, Agnieszka Druzd-Sitek, Jan Walewski, Magdalena Chechlinska, Jan Konrad Siwicki
• Format: Article
• Language: English
• Published: MDPI AG 2019-10-01
• Series: Cancers
• Subjects: central nervous system (cns) lymphoma; microrna; brain stereotactic biopsy; cns disease; neurological disease; cerebrospinal fluid; differential diagnosis; brain tumor
• Online Access: https://www.mdpi.com/2072-6694/11/11/1647

Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive, extranodal form of non-Hodgkin lymphoma, predominantly diagnosed as primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL). Fast and precise diagnosis of PCNSL is critical yet challenging. microRNAs, important regulators in physiology and pathology are potential biomarkers. In 131 patients with CNS DLBCL and with non-malignant brain lesions (n-ML), miR-21, miR-19b and miR-92a, miR-155, miR-196b, miR-let-7b, miR-125b, and miR-9 were examined by RT-qPCR in brain biopsy samples (formalin-fixed paraffin-embedded tissues, FFPET; CNS DLBCL, <i>n</i> = 52; n-ML, <i>n</i> = 42) and cerebrospinal fluid samples (CSF; CNS DLBCL, <i>n</i> = 30; n-ML, <i>n</i> = 23) taken for routine diagnosis. FFPET samples were split into study and validation sets. Significantly higher CSF levels of miR-21, miR-19b, and miR-92a were identified in PCNSL but not in n-ML, and differentiated PCNSL from n-ML with 63.33% sensitivity and 80.77% specificity. In FFPETs, miR-155 and miR-196b were significantly overexpressed and miR-let-7b, miR-125b, and miR-9 were downregulated in PCNSL as compared to n-ML. Combined miR-155 and miR-let-7b expression levels in FFPETs discriminated PCNSL and n-ML with a 97% accuracy. In conclusion, tissue miR-155, miR-196b, miR-9, miR-125b, and miR-let-7b expression profiles differentiate PCNSL from n-ML. PCNSL CSFs and the relevant biopsy samples are characterized by specific, different microRNA profiles. A logistic regression model is proposed to discriminate between PCNSL and non-malignant brain lesions. None of the examined microRNAs influenced overall survival of PCNSL patients. Further ongoing developments involve next generation sequencing-based profiling of biopsy and CSF samples.